author-photo

David Tsang

5

Papers

1163

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness

2018 European Urology Oncology
Show All
- Source
- Cite
- Save
Citations (9)
Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (32)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

2016 The Lancet
Show All
- Source
- Cite
- Save
Citations (1103)
19LBA Docetaxel (Doc) +/− zoledronic acid (ZA) for hormone-naive prostate cancer: First overall survival results from STAMPEDE & treatment effects within subgroups (NCT00268476)

2015 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (12)
Docetaxel (Doc) plus /- zoledronic acid (ZA) for hormone-naive prostate cancer: First overall survival results from STAMPEDE & treatment effects within subgroups (NCT00268476)

2015
Show All
- Source
- Cite
- Save
Citations (7)